
## Sayed Hashemi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1001315/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral― Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1081-1089.	1.1	176
2	Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. Lung Cancer, 2018, 124, 130-134.	2.0	12
3	Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2020, 38, 9593-9593.	1.6	12
4	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer, 2021, 152, 149-156.	2.0	11
5	Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC Journal of Clinical Oncology, 2021, 39, 9112-9112.	1.6	9
6	Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment Journal of Clinical Oncology, 2017, 35, 9042-9042.	1.6	8
7	The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis. JTO Clinical and Research Reports, 2021, 2, 100195.	1.1	4
8	Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC Journal of Clinical Oncology, 2022, 40, 9065-9065.	1.6	4
9	Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non–small cell lung cancer Journal of Clinical Oncology, 2022, 40, 9066-9066.	1.6	1